Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471

Abstract

New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

1 - 38 . (canceled) 
     
     
         39 . A crystalline form of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid having an X-ray diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 16.2 and 20.6°. 
     
     
         40 . A crystalline compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 16.2, 20.6 and 17.7°. 
     
     
         41 . A crystalline form of a compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 16.2, 20.6, 17.7, 10.8 and 15.5°. 
     
     
         42 . A crystalline form of a compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 16.2, 20.6, 17.7, 10.8, 15.5, 20.9, 26.1, 11.6 and 26.7°. 
     
     
         43 . A crystalline compound as claimed in  claim 39  having an X-ray diffraction pattern, using CuKa radiation, substantially the same as shown in  FIG. 6 . 
     
     
         44 . A pharmaceutical composition, which comprises a compound according to any one of  claim 39  in association with a pharmaceutically-acceptable diluent or carrier. 
     
     
         45 . A method of producing a 11βHSD1 inhibitory effect by administering an effective amount of a compound according to  claim 39  to a mammal in need of such treatment. 
     
     
         46 . A method according to  claim 45  wherein the 11βHSD1 inhibitory effect is to treat type 2 diabetes.